JP2014508748A - 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法 - Google Patents

黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法 Download PDF

Info

Publication number
JP2014508748A
JP2014508748A JP2013553501A JP2013553501A JP2014508748A JP 2014508748 A JP2014508748 A JP 2014508748A JP 2013553501 A JP2013553501 A JP 2013553501A JP 2013553501 A JP2013553501 A JP 2013553501A JP 2014508748 A JP2014508748 A JP 2014508748A
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding fragment
alpha toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013553501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508748A5 (enExample
Inventor
セルマン，ブレット
トカツィク，クリスティーン
フア，レイ
チャウダリー，パーサ
ヴァーキー，リーナ
ダムシュローダー，メリッサ
ペン，リー
オガネスヤン，ヴァエ
ヒリアード，ジェームズ，ジョンソン
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46639171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2014508748(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2014508748A publication Critical patent/JP2014508748A/ja
Publication of JP2014508748A5 publication Critical patent/JP2014508748A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/709—Toxin induced
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
JP2013553501A 2011-02-08 2012-02-07 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法 Pending JP2014508748A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161440581P 2011-02-08 2011-02-08
US61/440,581 2011-02-08
PCT/US2012/024201 WO2012109285A2 (en) 2011-02-08 2012-02-07 Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017023905A Division JP6367393B2 (ja) 2011-02-08 2017-02-13 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法

Publications (2)

Publication Number Publication Date
JP2014508748A true JP2014508748A (ja) 2014-04-10
JP2014508748A5 JP2014508748A5 (enExample) 2015-03-26

Family

ID=46639171

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013553501A Pending JP2014508748A (ja) 2011-02-08 2012-02-07 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法
JP2017023905A Active JP6367393B2 (ja) 2011-02-08 2017-02-13 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法
JP2018127340A Active JP6723293B2 (ja) 2011-02-08 2018-07-04 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法
JP2020108083A Active JP7047017B2 (ja) 2011-02-08 2020-06-23 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017023905A Active JP6367393B2 (ja) 2011-02-08 2017-02-13 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法
JP2018127340A Active JP6723293B2 (ja) 2011-02-08 2018-07-04 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法
JP2020108083A Active JP7047017B2 (ja) 2011-02-08 2020-06-23 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法

Country Status (24)

Country Link
US (1) US9527905B2 (enExample)
EP (2) EP2673373B3 (enExample)
JP (4) JP2014508748A (enExample)
KR (1) KR101993839B1 (enExample)
CN (2) CN103443285B9 (enExample)
AU (1) AU2012214531C1 (enExample)
BR (1) BR112013020086B1 (enExample)
CA (1) CA2826566C (enExample)
CY (1) CY1121389T1 (enExample)
DK (1) DK2673373T6 (enExample)
ES (1) ES2709065T7 (enExample)
HR (1) HRP20182017T4 (enExample)
HU (1) HUE040734T2 (enExample)
LT (1) LT2673373T (enExample)
MX (3) MX345285B (enExample)
PL (1) PL2673373T6 (enExample)
PT (1) PT2673373T (enExample)
RS (1) RS58190B2 (enExample)
RU (1) RU2620065C2 (enExample)
SG (3) SG10201913690SA (enExample)
SI (1) SI2673373T1 (enExample)
SM (1) SMT201800635T1 (enExample)
TR (1) TR201817932T4 (enExample)
WO (1) WO2012109285A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456767A (zh) * 2014-06-19 2017-02-22 免疫医疗有限责任公司 多细菌感染的治疗
JP2022548937A (ja) * 2019-09-20 2022-11-22 マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド 抗α溶血素抗体およびその使用
JP2024503425A (ja) * 2021-01-11 2024-01-25 星濟生物（蘇州）有限公司 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014100111A (ru) 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
HRP20201370T1 (hr) 2011-11-07 2020-11-27 Medimmune Limited Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
BR112015010240A2 (pt) * 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
BR112015010125A2 (pt) * 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
KR20210083389A (ko) * 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
RU2016119052A3 (en) * 2013-10-17 2018-09-10 Arsanis Biosciences Gmbh Cross-reactive Staphylococcus aureus antibody sequences
WO2015109012A1 (en) * 2014-01-14 2015-07-23 Integrated Biotherapeutics, Inc. Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US20180017559A1 (en) * 2014-08-12 2018-01-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
KR102614189B1 (ko) 2014-11-17 2023-12-18 리제너론 파아마슈티컬스, 인크. Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
JP6889701B2 (ja) 2015-09-24 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルファ溶血素バリアント
WO2017075188A2 (en) * 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
WO2018148494A1 (en) 2017-02-09 2018-08-16 Bluefin Biomedicine, Inc. Anti-ilt3 antibodies and antibody drug conjugates
CN108456250B (zh) * 2017-02-17 2025-11-28 恺兴生命科技(上海)有限公司 靶向il-13ra2的抗体及其应用
CN109384844B (zh) * 2017-08-04 2020-12-18 中国人民解放军军事医学科学院基础医学研究所 一种抗金黄色葡萄球菌α溶血素单克隆抗体及应用
JP7525471B2 (ja) 2018-07-24 2024-07-30 メディミューン，エルエルシー Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体
US11396542B2 (en) 2018-08-21 2022-07-26 Synkrino Biotherapeutics, Inc. Astrotactin1-based compositions and pharmaceutical formulations
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
BR112021006622A2 (pt) 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus
TWI895248B (zh) 2018-10-09 2025-09-01 美商麥迪紐有限責任公司 針對金黃色葡萄球菌白血球毒素的抗體
CN113811544A (zh) * 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
CN113444173A (zh) 2020-03-25 2021-09-28 兴盟生物医药(苏州)有限公司 金黄色葡萄球菌α-毒素特异性抗体及其应用
CN112941136B (zh) * 2021-03-24 2023-04-28 成都欧林生物科技股份有限公司 一种重组金黄色葡萄球菌疫苗hi抗原蛋白的纯化方法
CN114455048B (zh) * 2022-03-02 2023-03-14 江苏微导纳米科技股份有限公司 一种桨杆
CN117106077B (zh) * 2022-04-28 2024-07-16 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN116023486B (zh) * 2023-01-10 2024-10-08 西北农林科技大学 金黄色葡萄球菌α-溶血素纳米抗体、制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010538015A (ja) * 2007-08-31 2010-12-09 ユニバーシティ オブ シカゴ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JP2000510582A (ja) 1996-04-25 2000-08-15 ゼニコン・サイエンシーズ・コーポレーション 微粒子標識を使用した分析物アッセイ
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
ATE458006T1 (de) * 2003-05-14 2010-03-15 Kenta Biotech Ag Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa
CN1324049C (zh) * 2003-08-04 2007-07-04 中国疾病预防控制中心病毒病预防控制所 人源抗sars冠状病毒基因工程抗体
PT1737891E (pt) * 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
JP2009526520A (ja) 2006-01-17 2009-07-23 バイオレックス セラピュティックス インク 植物中でのｎ−グリカンのヒト化及び最適化のための組成物及び方法
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US20080131457A1 (en) * 2006-06-12 2008-06-05 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
WO2009029132A2 (en) * 2007-05-31 2009-03-05 Merck & Co., Inc. Antigen-binding proteins targeting s. aureus orf0657n
PL2188313T3 (pl) * 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
US8172115B1 (en) 2008-04-10 2012-05-08 Spencer Forrest, Inc. Hair building solids dispenser for one handed operation
JP2011526792A (ja) * 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
GB2467939A (en) * 2009-02-20 2010-08-25 Univ Sheffield Removal of bacteria from media
SA110310528B1 (ar) * 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
BR112015010125A2 (pt) 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010538015A (ja) * 2007-08-31 2010-12-09 ユニバーシティ オブ シカゴ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6016000328; Ｉｎｆｅｃｔ．　Ｉｍｍｕｎ．　（２００９）　ｖｏｌ．７７，　ｎｏ．７，　ｐ．２７１２-２７１８ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456767A (zh) * 2014-06-19 2017-02-22 免疫医疗有限责任公司 多细菌感染的治疗
JP2017519768A (ja) * 2014-06-19 2017-07-20 メディミューン，エルエルシー 多細菌性感染の治療
JP2021063090A (ja) * 2014-06-19 2021-04-22 メディミューン，エルエルシー 多細菌性感染の治療
CN106456767B (zh) * 2014-06-19 2021-07-09 免疫医疗有限责任公司 多细菌感染的治疗
JP2022548937A (ja) * 2019-09-20 2022-11-22 マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド 抗α溶血素抗体およびその使用
JP2024503425A (ja) * 2021-01-11 2024-01-25 星濟生物（蘇州）有限公司 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用

Also Published As

Publication number Publication date
JP6723293B2 (ja) 2020-07-15
TR201817932T4 (en) 2019-02-21
US20140072577A1 (en) 2014-03-13
ES2709065T7 (es) 2021-12-09
SG10201600899PA (en) 2016-03-30
JP7047017B2 (ja) 2022-04-04
BR112013020086A2 (pt) 2016-11-22
MX345285B (es) 2017-01-24
PL2673373T3 (pl) 2019-04-30
EP2673373A2 (en) 2013-12-18
MX2013009127A (es) 2014-01-31
EP2673373B3 (en) 2021-06-02
SG10201913690SA (en) 2020-03-30
CN103443285B (zh) 2017-06-23
KR20140019344A (ko) 2014-02-14
US9527905B2 (en) 2016-12-27
DK2673373T3 (da) 2019-01-02
KR101993839B1 (ko) 2019-06-28
HRP20182017T4 (hr) 2021-08-20
CN107474133B (zh) 2021-10-15
CN107474133A (zh) 2017-12-15
RS58190B2 (sr) 2021-08-31
JP2019011329A (ja) 2019-01-24
PL2673373T6 (pl) 2021-09-27
RU2620065C2 (ru) 2017-05-22
ES2709065T3 (es) 2019-04-15
EP2673373B1 (en) 2018-08-29
SMT201800635T1 (it) 2019-01-11
AU2012214531B2 (en) 2017-03-16
JP6367393B2 (ja) 2018-08-01
HK1248257A1 (zh) 2018-10-12
CA2826566A1 (en) 2012-08-16
CN103443285A (zh) 2013-12-11
CA2826566C (en) 2022-09-13
EP3470526A3 (en) 2019-07-17
RS58190B1 (sr) 2019-03-29
CN103443285B9 (zh) 2018-04-24
DK2673373T6 (da) 2021-08-23
JP2020172489A (ja) 2020-10-22
BR112013020086B1 (pt) 2020-12-08
EP2673373A4 (en) 2015-06-17
WO2012109285A3 (en) 2012-10-04
RU2013141134A (ru) 2015-03-20
EP3470526A2 (en) 2019-04-17
SG192212A1 (en) 2013-09-30
MX375113B (es) 2025-03-04
HRP20182017T1 (hr) 2019-02-08
HUE040734T2 (hu) 2019-03-28
SI2673373T1 (sl) 2019-03-29
JP2017128575A (ja) 2017-07-27
LT2673373T (lt) 2019-01-25
MX2020009700A (es) 2020-10-07
PT2673373T (pt) 2018-12-05
AU2012214531C1 (en) 2021-07-29
WO2012109285A2 (en) 2012-08-16
CY1121389T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
JP7047017B2 (ja) 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法
AU2012214531A1 (en) Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use
JP6797111B2 (ja) イヌｐｄ−ｌ１と結合するｐｄ−ｌ１抗体
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
US11542329B2 (en) Antibodies targeting Glycoprotein VI
US20240101649A1 (en) ANTI-CfaE ANTIBODIES AND METHODS OF USE
HK40007158A (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
HK1248257B (zh) 特异性结合金黄色葡萄球菌α毒素的抗体以及使用方法
HK1191977B (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
HK1191977A (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
HK1191978B (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
HK1191978A (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
HK40061870B (zh) 中和抗乙型流感抗体及其用途
HK40057425B (zh) 中和抗乙型流感抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161011